Welcome to our dedicated page for Sotera Health Co SEC filings (Ticker: SHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sotera Health Company (SHC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sotera Health is a Nasdaq-listed provider of mission-critical sterilization solutions, lab testing and advisory services for the healthcare industry, operating through its Sterigenics, Nordion and Nelson Labs businesses.
Investors can review Form 8-K filings that report material events such as quarterly financial results, secondary offerings of common stock by selling stockholders, amendments to credit agreements and settlements of specific legal matters. For example, recent 8-Ks describe secondary offerings in which affiliates of Warburg Pincus LLC and GTCR LLC sold shares of SHC, with the company noting that it did not receive proceeds from those sales. Other 8-Ks outline amendments to a first lien credit agreement and the terms of repriced term loans maturing in 2031.
Filings also discuss legal and regulatory developments, including a binding term sheet to resolve a defined group of ethylene oxide claims related to a former Sterigenics facility, and broader risk factors associated with EO and Co-60, regulatory compliance, international operations and leverage. These disclosures help readers understand the legal, operational and financial context around Sotera Health’s sterilization and lab testing activities.
On Stock Titan, users can track new SHC filings as they appear on EDGAR and use AI-powered summaries to interpret complex documents. This includes understanding the implications of current reports on Form 8-K, as well as locating annual and quarterly reports when they are filed, to see segment information for Sterigenics, Nordion and Nelson Labs, capital structure details and updated risk factor discussions.
Sotera Health Company (SHC) filing a Form 144 notifies the proposed sale of 126,611 shares of common stock through Charles Schwab with an aggregate market value of $2,040,969. The shares represent part of equity compensation originally acquired from the issuer on 11/20/2020 and are scheduled for sale approximately on 08/22/2025 on Nasdaq.
The filing discloses the number of shares outstanding as 284,046,606, and states there were no reported sales by the person in the past three months. The filer certifies they have no undisclosed material adverse information. This is a routine Rule 144 notice of an insider-proposed sale of previously issued equity compensation.
Sotera Health reported consolidated net revenues of $294.3 million for the three months ended June 30, 2025, up from $276.6 million a year earlier, driven by higher service revenue in Sterigenics and steady contributions from Nordion and Nelson Labs. Gross profit rose to $166.6 million versus $152.8 million, and cash and cash equivalents increased to $332.4 million from $277.2 million at year-end, supporting liquidity.
The company recorded $34.0 million of Illinois EO litigation settlements during the quarter and established a $64.9 million reserve reflected in accrued liabilities and operating cash flows. Net income for the quarter was $8.0 million (basic EPS $0.03), while the six-month period produced a net loss of $5.3 million compared with net income of $15.1 million in the prior year period. Total assets were $3.217 billion, total liabilities $2.705 billion, and total equity improved to $511.3 million.
Sotera Health Company furnished a press release reporting its financial results for the quarter ended June 30, 2025 and scheduled a conference call at 9:00 a.m. Eastern Time to discuss those results. The press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference into the report.
The filing clarifies that the press release and related information are being furnished, not filed, and therefore are not subject to Section 18 liability. This Form 8-K does not include any financial figures or performance metrics; readers should consult the attached Exhibit 99.1 for the detailed results and disclosures.